Streetbeat News

Regulatory

BIIB

BMY

JNJ

MRK

NVO

Sen. Bernie Sanders criticized the high cost of healthcare in the U.S., highlighting the financial burden on patients. He specifically mentioned the high prices of drugs from Novo Nordisk, Eisai Co Ltd, Biogen Inc, Johnson & Johnson, Merck, and Bristol-Myers Squibb.

Portfolio Pulse from Benzinga Neuro

July 16, 2024 | 1:36 am

BEN

BLK

ETHUSD

VAN

The SEC has provisionally approved at least three Ethereum-based ETFs, with trading expected to start by July 23, provided no last-minute issues arise. Asset managers like BlackRock, VanEck, and Franklin Templeton are among those likely to launch these ETFs. This development could lead to significant capital inflows into Ethereum, potentially boosting its value.

Portfolio Pulse from Aniket Verma

July 16, 2024 | 1:10 am

ALZN

Trading for ALZN was halted at 7:50:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 11:50 pm

DUK

Duke Energy Florida has reached an agreement with consumer representatives and business groups, and the company expects customer bills to decrease in 2025 compared to 2024.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:49 pm

CCSO

CUT

FPX

LBAY

SMN

Shipping costs for a 40-foot container from Shanghai to New York have surged to nearly $10,000 due to ships avoiding the Suez Canal amid Houthi rebel threats. The Drewry World Container Index spot rate hit $9,387, more than double the February rate. Concerns over potential tariffs if Trump wins the 2024 election are also causing importers to rush shipments. ETFs tracking shipping container stocks saw mixed performance.

Portfolio Pulse from Michael Juliano

July 15, 2024 | 8:46 pm

CRBG

Corebridge Financial, Inc. announced the effectiveness of its Form S-4 Registration Statement for the exchange of up to $500 million of its 6.050% Senior Notes due 2033. The exchange offer will expire on August 12, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:11 pm

KYTX

Kyverna Therapeutics shares are trading higher after the company announced it received FDA Regenerative Medicine Advanced Therapy designation for KYV-101 in the treatment of patients with refractory stiff-person syndrome.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:10 pm

ETON

Eton Pharmaceuticals shares are trading higher following the FDA's acceptance of the New Drug Application for ET-400.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:08 pm

RGEN

Repligen has discovered unauthorized access to its information systems. The company has engaged cybersecurity experts and notified law enforcement. The incident has not impacted business operations or financial condition. An investigation is ongoing to determine the full impact and necessary notifications.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:08 pm

ETON

Eton Pharmaceuticals has received FDA acceptance for its New Drug Application (NDA) for ET-400. The Prescription Drug User Fee Act (PDUFA) target action date is set for February 28, 2025. The product has patent protection through 2043.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:07 pm